RZLT Rezolute Inc
Price (delayed)
$4.99
Market cap
$200.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$196.72M
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric
Highlights
RZLT's debt is down by 6% since the previous quarter
Rezolute's EPS has shrunk by 61% YoY and by 3.6% QoQ
Rezolute's quick ratio has plunged by 51% YoY
Key stats
What are the main financial stats of RZLT
Market
Valuations
Earnings
Shares outstanding
40.14M
Market cap
$200.27M
Enterprise value
$196.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.79
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$58.21M
EBITDA
-$57.66M
Free cash flow
-$50.2M
Per share
Balance sheet
Liquidity
EPS
-$1.14
Free cash flow per share
-$0.99
Book value per share
$1.79
Revenue per share
$0
TBVPS
$1.73
Total assets
$87.74M
Total liabilities
$16.88M
Debt
$2.37M
Equity
$70.86M
Working capital
$75.25M
Debt to equity
0.03
Current ratio
11.82
Quick ratio
11.5
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.6%
Return on equity
-60.9%
Return on invested capital
-63.5%
Return on capital employed
-72.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RZLT stock price
How has the Rezolute stock price performed over time
Intraday
0%
1 week
-2.92%
1 month
17.69%
1 year
234.9%
YTD
402.77%
QTD
16.05%
Financial performance
How have Rezolute's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$61.56M
Net income
-$58.21M
Gross margin
N/A
Net margin
N/A
Rezolute's net income has decreased by 20% YoY and by 2.4% from the previous quarter
Rezolute's operating income has decreased by 16% YoY
Growth
What is Rezolute's growth rate over time
Valuation
What is Rezolute stock price valuation
P/E
N/A
P/B
2.79
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rezolute's EPS has shrunk by 61% YoY and by 3.6% QoQ
Rezolute's equity has decreased by 44% YoY and by 23% QoQ
Efficiency
How efficient is Rezolute business performance
The ROE has dropped by 79% year-on-year and by 18% since the previous quarter
The company's return on invested capital has surged by 68% YoY but it fell by 8% QoQ
RZLT's return on assets has dropped by 67% year-on-year and by 14% since the previous quarter
Dividends
What is RZLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RZLT.
Financial health
How did Rezolute financials performed over time
The total liabilities has soared by 145% YoY and by 62% QoQ
Rezolute's current ratio has plunged by 51% YoY
RZLT's debt is 97% smaller than its equity
RZLT's debt to equity has surged by 50% year-on-year
Rezolute's equity has decreased by 44% YoY and by 23% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.